Clinical trials
Other Solid Tumors clinical trials
Below are recruiting other solid tumors clinical trials, each written for real people, not researchers. We’re tracking 1,687 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06658353RecruitingPhase 3
Study of VC004 for advanced solid tumors
This trial tests a new drug called VC004 for people with advanced solid tumors that have spread. It aims to see if the drug can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 12 years+ - NCT06499350RecruitingPhase 1/Phase 2
New combo for advanced solid tumors after standard therapy
This trial tests a new combination of drugs (FC084CSA plus tislelizumab) for people with advanced solid tumors, especially lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It may be an option if you've tried standard treatments and they no longer work.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06350006RecruitingPhase 1
Testing SHR-A1904 combinations for CLDN18.2-positive advanced tumors
This study tests an experimental drug combination for people with advanced solid tumors that have a specific protein called CLDN18.2. It aims to see if the combination works better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT06979674RecruitingPhase 1
ESG406 for advanced solid tumors
This trial tests a new drug called ESG406 in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and helps shrink tumors.
Chongqing, Chongqing MunicipalityAges 18–80 - NCT06990464RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial is testing an investigational drug called SIBP-A19 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
Fuzhou, FujianAges 18–75 - NCT06414460RecruitingPhase 1/Phase 2
ISM3412 for advanced solid tumors with MTAP deletion
This study tests a new oral drug called ISM3412 for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug can shrink tumors or slow their growth.
Denver, ColoradoAges 18 years+ - NCT06512116RecruitingPhase 1
Testing SIBP-A17 for advanced solid tumors with HER2
This trial tests a new drug called SIBP-A17 for advanced solid tumors that have not responded to other treatments. It focuses on tumors that have a protein called HER2, and the goal is to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07192107RecruitingPhase 1/Phase 2
Study of MHB042C for advanced solid tumors
This trial tests a new drug called MHB042C for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective.
Guangzhou, GuangdongAges 18 years+ - NCT07050459RecruitingPhase 1
Study of SIM0686 for advanced solid tumors
This trial tests a new drug (SIM0686) in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how it affects tumors that have a specific protein called FGFR2b on their surface.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07374419RecruitingPhase 1/Phase 2
Atamparib for advanced lung cancer with KRAS mutation
This trial tests a drug called Atamparib for people with advanced lung cancer that has a specific genetic change called a KRAS mutation. It is for patients whose cancer has continued to grow after at least one standard treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07583654RecruitingPhase 1
Testing a New mRNA Cancer Treatment for Advanced Solid Tumors
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
Chengdu, SichuanAges 18–70 - NCT04785196RecruitingPhase 1/Phase 2
Testing an MDM2 drug plus an immune therapy for advanced tumors
This trial tests APG-115 together with a PD-1 immune therapy in people with advanced liposarcoma or other advanced solid tumors. It may help by blocking tumor growth through a mix of direct tumor targeting and immune system activation.
Guangzhou, GuangdongAges 18 years+ - NCT05338658RecruitingPhase 1
Test drug PAT in adults with solid tumors
This Phase 1 study tests PAT in adults with solid tumor cancers who meet specific immune and health criteria. Because it’s an early safety-and-dosing study, it may help researchers learn whether PAT can be given safely and whether it shows any cancer activity in the right patients.
Minneapolis, MinnesotaAges 18 years+ - NCT05470348RecruitingPhase 1
Test drug BL-B01D1 for advanced breast and other solid cancers
This Phase 1 trial tests BL-B01D1 in people with advanced (unresectable or metastatic) breast cancer and certain other solid tumors that have not worked with standard treatment. The goal is to learn if the drug can be given safely and to see whether it shows signs of benefit.
Guangzhou, GuangdongAges 18–75 - NCT05732831RecruitingPhase 1/Phase 2
Study drug for tumors with MTAP loss
This Phase 1/2 trial tests TNG462 (with or without pembrolizumab, depending on the plan) in solid tumors that have lost MTAP. The goal is to check safety and learn whether the treatment can help people with these specific tumor changes.
Palo Alto, CaliforniaAges 18 years+ - NCT05768139RecruitingPhase 1/Phase 2
Testing a new targeted drug for advanced solid tumors with PI3Kα mutation
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
Los Angeles, CaliforniaAges 18 years+ - NCT05803018RecruitingPhase 1/Phase 2
Study drug for advanced gynecologic cancer that stopped working
This Phase 1/2 study tests BL-B01D1 in people with recurrent or metastatic gynecologic cancers (such as ovarian, uterine, or cervical cancer) when standard treatments have failed or aren’t options. It focuses on how well the drug works and whether it can be given safely.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05828459RecruitingPhase 1
Testing a new anti-cancer drug in advanced cancers
This early Phase 1 study tests OT-A201 (a first-time-in-humans drug) in people with certain relapsed or advanced cancers. It helps doctors learn the safest dose and how the treatment may work for cancers that have already been treated.
MontpellierAges 18 years+ - NCT05965856RecruitingPhase 2
Testing two antibody medicines for advanced bladder and other cancers
This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06063681RecruitingPhase 1
Testing a new ENPPI inhibitor for advanced solid tumors
This trial tests a new drug, SR-8541A, that blocks an enzyme called ENPPI, which may help slow or stop tumor growth. It is for people with advanced or metastatic solid tumors who have not responded to other treatments or have no standard options.
Randwick, New South WalesAges 18 years+ - NCT06178614RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT06190886RecruitingPhase 1
First-in-human study of PTX-912 for advanced solid tumors
This trial tests a new drug called PTX-912 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It is a first-in-human study, meaning this is the first time PTX-912 is being given to people, to see how safe it is and how well it works.
Duarte, CaliforniaAges 18 years+ - NCT06234423RecruitingPhase 1
A study of CUSP06 for advanced solid tumors
This study tests a new drug called CUSP06 for people with advanced solid tumors, especially ovarian cancer that has stopped responding to platinum chemotherapy. It may help if standard treatments no longer work.
Denver, ColoradoAges 18 years+ - NCT06431594RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug called Mocertatug Rezetecan for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called B7-H4 on cancer cells to try to slow or shrink the tumor.
Birmingham, AlabamaAges 18 years+
Hear when a new Other Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other solid tumors?
- Yes. Clin2 currently lists 1,687 recruiting other solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.